# US Valley Fever Market

> US Valley Fever Market Research Report By Types of Treatments (Fluconazole, Itraconazole, Voriconazole, Posaconazole, Others) and By Site of Infection (Skin, Liver, Bones, Heart, Brain, Membranes That Surround the Brain and Spinal Cord, Others) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 3.44%
- **2024:** $ 288.4 Million
- **2025:** $ 298.32 Million
- **2035:** $ 418.54 Million
- **Key Players:** Astellas Pharma (JP), Gilead Sciences (US), Merck & Co (US), Pfizer (US), Bristol-Myers Squibb (US), Amgen (US), Novartis (CH), Sanofi (FR), Eli Lilly and Company (US)

**Report ID:** MRFR/Pharma/18534-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-valley-fever-market-20081

---

## Market Summary

## **US Valley Fever Market Overview**

As per MRFR analysis, the US Valley Fever Market Size was estimated at 277.2 (USD Million) in 2023. The US Valley Fever Market Industry is expected to grow from 288.4(USD Million) in 2024 to 461.46 (USD Million) by 2035. The US Valley Fever Market CAGR (growth rate) is expected to be around 4.366% during the forecast period (2025 - 2035).

### **Key US Valley Fever Market Trends Highlighted**

The US Valley Fever market is influenced by several key market drivers that have emerged in recent years. One major driver is the increasing awareness and diagnosis of Valley Fever, primarily caused by the fungus Coccidioides immitis. As healthcare professionals become more informed about the disease, its prevalence in the Southwestern United States, particularly in California and Arizona, has led to improved detection rates.

Furthermore, the growing population in endemic areas contributes to a higher incidence of the disease, prompting both regional health authorities and private sectors to focus more on research, treatment, and prevention strategies. Opportunities to be explored in this market include the development of new diagnostic tools and treatment options. With the advancement in molecular diagnostics and the demand for rapid testing methods, there is a potential for innovative solutions that can improve patient outcomes.

Additionally, increased community education initiatives can help raise awareness and encourage early treatment, reducing the healthcare burden associated with Valley Fever. Recent trends indicate a significant rise in public health campaigns aimed at educating at-risk populations about the symptoms and dangers of Valley Fever. These campaigns target areas where the disease is endemic, fostering a better understanding of the disease and leading to prompt medical consultation when symptoms arise.

Moreover, the focus on preventative measures, such as habitat management and public health guidelines, is also becoming more prominent, as communities recognize the importance of minimizing exposure to the Coccidioides fungus. Overall, the US Valley Fever market is evolving with these trends, reflecting a proactive approach to tackling a disease that has considerable implications for health within affected regions.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Valley Fever Market Drivers**

### **Growing Awareness and Diagnosis of Valley Fever**

In recent years, there has been a significant increase in the awareness regarding Valley Fever, primarily due to heightened public health initiatives and education campaigns spearheaded by the Centers for Disease Control and Prevention. This infectious disease, caused by the fungus Coccidioides, is endemic in certain areas of the United States, particularly in the Southwest. Reports indicate that the incidences of Valley Fever have seen a substantial rise, with an estimated 20,000 reported cases in 2020 compared to merely 5,000 in 2010.

This escalation emphasizes the need for enhanced diagnostic capabilities and improved healthcare response strategies. As healthcare providers increasingly recognize the symptoms and risk factors associated with Valley Fever, early diagnosis and treatment improve, facilitating better patient outcomes. Moreover, the increased investment in Research and Development (R&D) for diagnostic tests by major organizations like the National Institutes of Health is expected to foster more effective management of valley fever in the US [Valley Fever Market](../../../reports/valley-fever-market-1871) Industry.

### **Expand Research and Development Initiatives**

The surge in funding and support for Research and Development initiatives dedicated to Valley Fever is crucial for the advancement of treatment options and preventative measures. Various governmental bodies, including the National Institutes of Health (NIH), have reported an increase in grant allocations for research focused on infectious diseases. In the 2021 fiscal year, NIH allocated over $34 million specifically towards understanding and tackling fungal infections, which includes Valley Fever.

This increased focus on research is sparking innovations in therapeutics and vaccines, aimed at reducing the incidence and mortality related to the disease. The responsive engagement of established organizations in supporting R&D directly correlates with the anticipated growth in the US Valley Fever Market Industry.

### **Impact of Climate Change on Valley Fever Spread**

Climate change is altering environmental conditions that facilitate the growth and spread of the Coccidioides fungus responsible for Valley Fever, particularly impacting specific regions in the US such as California and Arizona. According to the US Geological Survey, rising temperatures and changing precipitation patterns have led to an uptick in the fungal spores that circulate in the air, thereby increasing the likelihood of outbreaks.

The agency projects that cases of Valley Fever could double in certain areas by 2050 if preventive measures are not adequately implemented. This directly corresponds with the growing concerns about public health and infectious diseases in relation to climate change, making it a crucial driver for investment, awareness, and resource allocation within the US Valley Fever Market Industry.

## **US Valley Fever Market Segment Insights**

### **Valley Fever Market Types of Treatments Insights**

The US Valley Fever Market encompasses a diverse range of treatments aimed at addressing the fungal infection caused by Coccidioides species. Among the Types of Treatments, Fluconazole stands out as a widely used antifungal medication, primarily due to its effectiveness in managing mild to moderate cases of Valley Fever, making it a mainstay in therapeutic regimens.

Itraconazole is another significant treatment option, known for its broader spectrum of activity against various fungal pathogens and is frequently employed in more severe cases or for patients with weakened immune systems. Voriconazole, with its advanced therapeutic properties, targets resistant strains and offers an alternative for patients who may not respond to first-line treatments, thereby expanding treatment options.

Posaconazole, although less commonly utilized for Valley Fever specifically, provides valuable treatment for patients with other underlying health issues and has garnered attention for its effectiveness against resistant fungi. Additionally, the "Others" category includes emerging treatments and clinical options currently under investigation, showcasing the ongoing innovation in the US Valley Fever treatment landscape.

The overall growth in awareness about Valley Fever, particularly in endemic regions of the Southwestern United States, has been complemented by advances in antifungal therapies, indicating strong potential for expansion in this segment. The rise in diagnoses and better reporting practices have created a heightened demand for effective treatments, propelling the US Valley Fever Market.

Market statistics indicate that the increasing incidence of Valley Fever is a contributing factor to the continued development and utilization of various antifungal medications, positioning the Types of Treatments segment as a crucial component in the ongoing management of this disease. The relevance of these treatments is further underscored by the change in climate and environmental factors leading to the resurgence of Coccidioides spores, thus emphasizing the urgency for effective treatment strategies in mitigating the impact of Valley Fever in affected populations.

Consequently, the continual evolution in antifungal agents underlines the importance of research and development in this field, promising not only enhanced treatment capabilities but also improved patient outcomes for those affected by this challenging fungal infection.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Valley Fever Market Site of Infection Insights**

The US Valley Fever Market segmentation focusing on the Site of Infection reveals a diverse range of complications that can arise from this fungal disease. Among the various sites, the skin is one of the key areas affected, often presenting as rashes or lesions, which raises significant awareness for early diagnosis and treatment.

The liver also plays a crucial role, as infections can lead to severe complications if not adequately managed, highlighting the necessity for effective treatment options. Bones represent another major site of infection, with potential to result in osteomyelitis, significantly impacting patient mobility and quality of life.

The heart can be seriously affected, leading to conditions such as pericarditis, which can complicate patient management and increase healthcare costs. The brain, along with the membranes that surround the brain and spinal cord, poses severe risks, including neurological deficits that can affect long-term outcomes. Other sites may vary widely, leading to a heterogeneous patient population that requires tailored healthcare solutions.

These variances in infection sites underscore the importance of targeted research and treatment strategies in the US Valley Fever Market, as each infection type presents unique challenges and opportunities for intervention.

## **US Valley Fever Market Key Players and Competitive Insights**

The US Valley Fever Market has garnered significant attention in recent years due to the increasing incidence of this fungal infection, particularly in endemic areas such as Arizona and California. Competitive insights within this market reveal a dynamic environment where various pharmaceutical and biotechnology firms are striving to develop effective therapeutics and diagnostics for Valley Fever, medically known as coccidioidomycosis.

With rising awareness among healthcare professionals and the general public, coupled with the increase in research and funding pertaining to this disease, companies are actively seeking to leverage innovative strategies to capture market share. The competition is shaped by factors such as product efficacy, safety profiles, regulatory approvals, and market access strategies, which influence how different players position themselves within the market.

Merck and Co has established a solid foothold in the US Valley Fever Market, driven by its robust R&D pipeline and commitment to infectious disease management. The company’s extensive experience in developing antifungal agents aids in addressing the challenges associated with Valley Fever treatment. Merck and Co possesses a strong brand reputation and a formidable distribution network, which enhances its ability to reach healthcare providers and patients affected by the disease.

The organization’s ongoing efforts to conduct clinical trials and collaborate with public health entities further fortify its presence in the market. Additionally, the company benefits from its well-resourced marketing strategies that help elevate awareness about Valley Fever, thereby driving demand for its products and contributing positively to its market position.

Valley Fever Solutions has emerged as a key player in the US Valley Fever Market, focusing on providing innovative solutions to combat this endemic fungal infection. The company specializes in developing diagnostics and treatment options aimed specifically at Valley Fever, and its portfolio includes advanced testing kits and therapeutics designed to enhance patient outcomes.

Valley Fever Solutions has cultivated strong partnerships with healthcare institutions and research organizations, leading to collective efforts in understanding and managing the disease better. The company's strengths lie in its agility and ability to quickly respond to emerging needs in the Valley Fever landscape, allowing for the potential for strategic mergers and acquisitions to expand its product offerings and market reach. Through continuous engagement in clinical trials and active participation in disease awareness campaigns, Valley Fever Solutions positions itself as a leader committed to addressing the needs of patients and healthcare providers within the US context.

### **Key Companies in the US Valley Fever Market Include**

## **US Valley Fever Market Industry Developments**

In recent months, the US Valley Fever Market has seen significant developments, particularly in response to increased awareness of the condition and advancements in treatment options. Companies such as Merck and Co. and Gilead Sciences have been focusing their efforts on Research and Development, aiming to enhance the efficacy of antifungal therapies.

Additionally, there has been a growing interest from firms like Valley Fever Solutions and Aimmune Therapeutics in innovative treatment approaches. In terms of mergers and acquisitions, no major transactions have been publicly reported involving the primary companies engaged in addressing Valley Fever, including Novartis and Horizon Therapeutics, as of late 2023.

The market valuation for various pharmaceutical companies targeting this condition has been on an upward trajectory, reflecting a heightened urgency for effective management solutions, especially in endemic regions of the US such as California and Arizona. Notably, public health initiatives by the Centers for Disease Control and Prevention (CDC) have underscored the importance of awareness and prevention efforts surrounding Valley Fever over the past few years, particularly during the outbreaks reported in the summer months of 2021 and 2022.

## **US Valley Fever Market Segmentation Insights**

### **Valley Fever Market Types of Treatments Outlook**

### **Valley Fever Market Site of Infection Outlook**

## Market Drivers

### Rising Incidence Rates

The valley fever market experiences growth due to the rising incidence rates of coccidioidomycosis, the disease caused by the fungus Coccidioides. In recent years, the number of reported cases has increased, particularly in the southwestern US, where environmental conditions favor the fungus's growth. According to the Centers for Disease Control and Prevention (CDC), the incidence rate has surged, with thousands of cases reported annually. This trend indicates a growing need for effective diagnostics and treatment options, thereby driving the valley fever market. As awareness of the disease spreads, healthcare providers are more likely to seek out innovative solutions, contributing to market expansion. The increasing burden of valley fever on public health systems further emphasizes the necessity for investment in research and development within the valley fever market.

### Increased Research Funding

This market is likely to benefit from increased research funding aimed at understanding and combating coccidioidomycosis.. Government and private organizations are recognizing the need for more comprehensive studies on the disease, its epidemiology, and potential treatment options. This influx of funding may lead to breakthroughs in therapeutic development and improved patient care strategies. Research initiatives focusing on vaccine development and novel antifungal agents are particularly promising. As funding continues to grow, the valley fever market may see a surge in innovative products and solutions, addressing the unmet needs of patients. This trend not only enhances the scientific understanding of valley fever but also positions the market for future growth.

### Growing Healthcare Expenditure

This market is influenced by the growing healthcare expenditure in the US.. As healthcare budgets expand, there is an increased focus on infectious diseases, including valley fever. This trend is reflected in the allocation of resources towards research, diagnostics, and treatment options for coccidioidomycosis. Higher healthcare spending allows for the development of advanced medical technologies and improved access to care for patients. Additionally, as more healthcare providers recognize the importance of addressing valley fever, the market is likely to see an increase in the availability of diagnostic tests and therapeutic options. This growing investment in healthcare infrastructure may ultimately lead to better management of valley fever cases, thereby enhancing the overall market landscape.

### Enhanced Public Health Initiatives

Public health initiatives aimed at increasing awareness and prevention of valley fever are pivotal in shaping the valley fever market. Government agencies and health organizations are actively promoting education about the disease, its symptoms, and preventive measures. These initiatives are crucial in regions where valley fever is endemic, as they encourage early diagnosis and treatment. The CDC has launched campaigns to inform the public about the risks associated with valley fever, which may lead to increased healthcare utilization. As more individuals become aware of the disease, the demand for diagnostic tests and treatment options is likely to rise, thereby stimulating growth in the valley fever market. This proactive approach not only aids in reducing the incidence of the disease but also enhances the overall market landscape.

### Technological Advancements in Diagnostics

Technological advancements in diagnostic methods are significantly influencing the valley fever market. Innovations such as molecular testing and serological assays have improved the accuracy and speed of diagnosing valley fever. These advancements allow for earlier detection of the disease, which is crucial for effective treatment. The introduction of rapid diagnostic tests has the potential to enhance patient outcomes and reduce healthcare costs. As healthcare providers increasingly adopt these technologies, the demand for diagnostic tools in the valley fever market is expected to grow. Furthermore, the integration of telemedicine and digital health solutions may facilitate access to diagnostic services, particularly in remote areas. This trend indicates a shift towards more efficient healthcare delivery, ultimately benefiting the valley fever market.

## Future Outlook

The [Valley Fever Market](https://www.marketresearchfuture.com/reports/valley-fever-market-1871) is projected to grow at a 3.44% CAGR from 2025 to 2035, driven by increased awareness, improved diagnostics, and rising healthcare investments.

**New opportunities:**

- Development of rapid diagnostic kits for early detection
- Expansion of telemedicine services for remote consultations
- Investment in targeted therapies to enhance treatment efficacy

By 2035, the valley fever market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Types of Treatments: Fluconazole (Largest) vs. Itraconazole (Fastest-Growing)

In the US valley fever market, the treatment segment showcases a notable diversification with various antifungal medications. Fluconazole continues to lead the segment due to its established efficacy and widespread use, capturing a significant market share. In contrast, Itraconazole has emerged as a preferred option for many physicians, thus witnessing rapid adoption and growth in recent years, supported by clinical studies that enhance its prescribing profile.

Driving factors for growth in this segment include an increasing awareness of valley fever, advancements in drug formulations, and a heightened focus on antifungal research. As healthcare providers seek more effective therapies, the demand for treatments such as Voriconazole and Posaconazole is also projected to rise. This evolving landscape reflects a shift towards targeted therapies that address specific needs of patients suffering from valley fever.

Fluconazole (Dominant) vs. Itraconazole (Emerging)

Fluconazole is currently the dominant treatment option in the US valley fever market, recognized for its broad-spectrum antifungal activity and proven track record. Its availability in generic form further contributes to its market share, making it accessible for a wider patient population. On the other hand, Itraconazole is classified as an emerging treatment, gaining traction due to its effectiveness in challenging cases and growing evidence supporting its use. The drug offers advantages in terms of both oral bioavailability and potential to treat severe infections, thus appealing to healthcare providers. This rivalry between the established Fluconazole and the rising star Itraconazole indicates a dynamic market environment, propelled by continuous research and evolving patient care standards.

### By Site of Infection: Lungs (Largest) vs. Skin (Fastest-Growing)

The market for the US valley fever segment is primarily dominated by infections in the lungs, which constitute the largest share within this category. Other significant sites include the skin, liver, and bones, with their shares being notably lower. Among these segment values, the lungs account for a substantial portion of infections attributed to valley fever, underlining the importance of respiratory care in treatment protocols.

In recent years, the skin infection segment has emerged as the fastest-growing area within the site of infection market. Increased awareness and advances in diagnostic techniques have contributed to the rising incidence of skin manifestations, while the lungs remain a persistent concern. Moreover, the rising number of cases and educational campaigns aimed at informing about valley fever are key drivers behind this growth trend across all sites of infection.

Lungs (Dominant) vs. Skin (Emerging)

The lungs represent the dominant site of infection for valley fever, primarily due to their susceptibility to respiratory pathogens. As the primary entry point for the causative agent, prevalence in this segment underscores the necessity for continued focus on pulmonary health. Contrastingly, skin infections are emerging as a significant concern, with increasing instances reported due to greater recognition of valley fever-related cutaneous symptoms. These infections serve as both a secondary complication and a potentially visible indicator, driving public awareness and timely intervention strategies. Both segments highlight the multifaceted nature of valley fever, necessitating a comprehensive management approach that addresses varying manifestations and promotes early diagnosis.

### By End-Use: Human (Largest) vs. Cattle (Fastest-Growing)

In the US valley fever market, the human segment constitutes the largest share, predominantly due to the increasing incidences of the disease within the population. Meanwhile, cattle also play a critical role, demonstrating significant market activity, particularly as awareness of the disease spreads among livestock producers. This segment's dynamics reflect a growing consciousness about animal health and the impact of valley fever in veterinary contexts, thus influencing overall market performance.

Regarding growth trends, factors such as climate change and the expansion of valley fever's geographic range are driving increased incidences in both humans and cattle. The rising human population and changing agricultural practices are facilitating the growth trajectory of the cattle segment, making it one of the fastest-growing areas. Veterinary interventions and awareness campaigns further support this growth, while the human segment remains focused on prevention, diagnosis, and treatment advancements.

Human (Dominant) vs. Cattle (Emerging)

The human segment is characterized by significant health implications and is often prioritized in research and healthcare initiatives within the US valley fever market. Its dominance is supported by high public awareness and targeted health policies aimed at mitigating disease impacts. In contrast, the cattle segment is emerging, driven by increasing concerns over livestock diseases and their broader implications for agricultural productivity. Cattle producers are acknowledging the risks associated with valley fever, leading to proactive health management strategies. Both segments are vital, but the focus on human health continues to dominate, while cattle's emerging status reflects a shift towards comprehensive agricultural health considerations.

## Competitive Benchmarking

The valley fever market exhibits a complex competitive landscape characterized by a mix of established pharmaceutical giants and emerging players. Key growth drivers include an increasing incidence of valley fever, heightened awareness among healthcare providers, and advancements in diagnostic technologies. Major companies such as Gilead Sciences (US), Merck & Co (US), and Astellas Pharma (JP) are strategically positioned to leverage these trends. Gilead Sciences (US) focuses on innovative therapeutic solutions, while Merck & Co (US) emphasizes partnerships to enhance its research capabilities. Astellas Pharma (JP) is investing in regional expansion to tap into underserved markets, collectively shaping a competitive environment that prioritizes innovation and strategic collaborations.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness. The market structure appears moderately fragmented, with a few dominant players exerting considerable influence. This fragmentation allows for niche players to emerge, fostering a dynamic competitive atmosphere where agility and adaptability are crucial for success.

In October  Gilead Sciences (US) announced a collaboration with a leading diagnostic firm to develop a rapid testing solution for valley fever. This strategic move is likely to enhance Gilead's portfolio by integrating diagnostics with therapeutic options, thereby streamlining patient management and potentially increasing market share. The collaboration underscores the importance of comprehensive solutions in addressing the complexities of valley fever treatment.

In September  Merck & Co (US) expanded its clinical trial program for a novel antifungal agent targeting valley fever. This initiative reflects Merck's commitment to innovation and its proactive approach to addressing unmet medical needs. By advancing its pipeline, Merck positions itself as a leader in the therapeutic landscape, potentially capturing a larger share of the market as new treatments become available.

In August  Astellas Pharma (JP) launched a targeted awareness campaign aimed at healthcare professionals in endemic regions. This initiative is significant as it not only educates providers about valley fever but also promotes Astellas' existing treatment options. By enhancing awareness, Astellas may improve diagnosis rates and treatment adherence, ultimately driving growth in its product offerings.

As of November  current competitive trends indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence in drug development and patient management. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift may redefine market dynamics, emphasizing the need for companies to adapt swiftly to changing healthcare demands.

## Recent News & Developments

In recent months, the US Valley Fever Market has seen significant developments, particularly in response to increased awareness of the condition and advancements in treatment options. Companies such as Merck and Co. and Gilead Sciences have been focusing their efforts on Research and Development, aiming to enhance the efficacy of antifungal therapies.

Additionally, there has been a growing interest from firms like Valley Fever Solutions and Aimmune Therapeutics in innovative treatment approaches. In terms of mergers and acquisitions, no major transactions have been publicly reported involving the primary companies engaged in addressing Valley Fever, including Novartis and Horizon Therapeutics, as of late 2023.

The market valuation for various pharmaceutical companies targeting this condition has been on an upward trajectory, reflecting a heightened urgency for effective management solutions, especially in endemic regions of the US such as California and Arizona. Notably, public health initiatives by the Centers for Disease Control and Prevention (CDC) have underscored the importance of awareness and prevention efforts surrounding Valley Fever over the past few years, particularly during the outbreaks reported in the summer months of 2021 and 2022.

## Report Scope

| MARKET SIZE 2024 | 288.4(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 298.32(USD Million) |
| MARKET SIZE 2035 | 418.54(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.44% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Astellas Pharma (JP), Gilead Sciences (US), Merck & Co (US), Pfizer (US), Bristol-Myers Squibb (US), Amgen (US), Novartis (CH), Sanofi (FR), Eli Lilly and Company (US) |
| Segments Covered | Types of Treatments, Site of Infection, End-Use |
| Key Market Opportunities | Advancements in diagnostic technologies enhance early detection and treatment options in the valley fever market. |
| Key Market Dynamics | Rising awareness and diagnosis of valley fever drive demand for innovative treatment options and improved patient care. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation of the US valley fever market in 2024?**
A: The overall market valuation of the US valley fever market was $288.4 Million in 2024.

**Q: What is the projected market valuation for the US valley fever market by 2035?**
A: The projected market valuation for the US valley fever market is $418.54 Million by 2035.

**Q: What is the expected CAGR for the US valley fever market during the forecast period 2025 - 2035?**
A: The expected CAGR for the US valley fever market during the forecast period 2025 - 2035 is 3.44%.

**Q: Which companies are considered key players in the US valley fever market?**
A: Key players in the US valley fever market include Astellas Pharma, Gilead Sciences, Merck & Co, Pfizer, Bristol-Myers Squibb, Amgen, Novartis, Sanofi, and Eli Lilly and Company.

**Q: What are the main types of treatments available in the US valley fever market?**
A: The main types of treatments in the US valley fever market include Fluconazole, Itraconazole, Voriconazole, Posaconazole, and others.

**Q: What was the market value for Fluconazole in 2024?**
A: The market value for Fluconazole in 2024 was between $80.0 Million and $115.0 Million.

**Q: How does the market value for lung infections compare to other sites of infection?**
A: The market value for lung infections was between $100.0 Million and $150.0 Million, making it the highest among other sites of infection.

**Q: What is the market value range for treatments targeting the liver in 2024?**
A: The market value range for treatments targeting the liver in 2024 was between $20.0 Million and $30.0 Million.

**Q: What is the projected market value for cattle in the US valley fever market by 2035?**
A: The projected market value for cattle in the US valley fever market is expected to be between $50.0 Million and $70.0 Million by 2035.

**Q: What is the market value for 'Others' in the end-use segment for 2024?**
A: The market value for 'Others' in the end-use segment was between $118.4 Million and $173.54 Million in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-valley-fever-market-20081*